Across geographies, approval, pricing and reimbursement of pharmaceuticals take place under varying timelines with different outcomes. There are some countries that may obtain access to new pharmaceuticals through early access schemes. Breakthrough and innovative products that are thought to have a profound impact on current standard of care are often eligible for quicker routes to access. This research sought to investigate how these schemes worked, where they were prevalent, and the outcomes of such schemes. The research was conducted through in-depth interviews with payers and clinicians across 10 EMEA markets. Of the 10 markets studied, 5 countries were identified to have either easier or quicker routes to access for new biopharmaceuticals (e. g., ATU in France and Algeria, law 648/96 in Italy, non-formulary access in Saudi Arabia, and the "white list" in Norway). Most often, these routes were reserved for products with orphan indications or products that were believed to significantly impact current standard of care. If pharmaceutical companies opt for the streamlined route, there are often significant restrictions imposed on the product, as well as a reduction in volume. If companies elect for the standard route to approval and reimbursement, the review process is often more rigorous, however, the decision is likely more permanent and the volume of product is larger. Frequently, if products opt for the faster route to access, this will serve as additional evidence for getting the product reimbursed at a later date for use in a wider population. New pharmaceutical products that are likely to dramatically change the treatment landscape or are active in orphan diseases should take advantage of these schemes. Physicians grasp at the opportunity to use efficacious products as early as possible and companies need to leverage the opportunity for streamlined access to products.